Skip to main content

Advertisement

Table 1 Trial characteristics

From: The fading of reported effectiveness. A meta-analysis of randomised controlled trials

  Pravastatin (n = 64) Atorvastatin (n = 35)
  Mean ± SD Min. Max. Mean ± SD Min. Max.
Year of publication 1995.28 ± 3.46 1990 2001 1999.40 ± 1.82 1996 2001
Reported effect size* -29.50 ± 4.16 -19.0 -39.0 -36.07 ± 3.70 -28.4 -44.2
Baseline 205.62 ± 47.78 134.4 344.0 198.05 ± 35.05 143.0 340.3
Study size 595.77 ± 1511.59 10 9014 328.71 ± 686.64 22 3916
Treatment group§ EG: 56 (87%); CG: 8 (13%) EG: 31 (89%); CG: 4 (11%)
  Timolol (n = 75) Latanoprost (n = 32)
  Mean ± SD Min. Max. Mean ± SD Min. Max.
Year of publication 1992.68 ± 6.99 1978 2001 1999.06 ± 2.00 1995 2001
Reported effect size -6.55 ± 1.56 -3.65 -11.3 -6.83 ± 1.53 -3.5 -9.8
Baseline 25.94 ± 2.49 20.8 38.7 24.07 ± 2.13 19.3 28.2
Study size 197.96 ± 249.59 12 1198 152.81 ± 195.57 20 829
Treatment group EG: 12 (16%); CG: 63 (84%) EG: 29 (91%); CG: 3 (9%)
  1. Abbreviations: n, number of trials that met selection criteria; SD, standard deviation; EG, experimental group; CG, control group.
  2. * Unit of measurement for reported effect size: Change of intraocular pressure measured in mmHg (Timolol, Latanoprost), change in low-density lipoprotein cholesterol measured in % (Pravastatin, Atorvastatin).
  3. Unit of measurement for baseline: Intraocular pressure measured in mmHg (Timolol, Latanoprost), low-density lipoprotein cholesterol measured in mg/dl (Pravastatin, Atorvastatin). To convert low-density lipoprotein cholesterol from milligrams per deciliter to millimoles per liter, multiply milligrams per deciliter by 0.0259.
  4. Unit of measurement for study size: Number of patients included in final analysis.
  5. § As the variable "treatment group" is either "experimental group" or "control group", exact frequencies and percentages are given.